轻型缺血性卒中或高危短暂性脑缺血发作后接受双联抗血小板治疗患者的低密度脂蛋白胆固醇水平与出血风险
该队列研究汇总CHANCE与CHANCE-2两项随机双盲安慰剂对照试验数据,纳入7440例中国轻型缺血性卒中或高危短暂性脑缺血发作并接受双联抗血小板治疗的患者,随访90天。结果显示LDL-C低于70 mg/dL与任何出血及重度或中度出血风险升高相关,替格瑞洛-阿司匹林组任何出血风险升高,氯吡格雷-阿司匹林组未观察到。
要点
- LDL-C低于70 mg/dL与3个月内任何出血风险升高相关(aHR 1.48)。
- LDL-C低于70 mg/dL与重度或中度出血风险升高相关(aHR 2.78)。
- 替格瑞洛-阿司匹林组任何出血风险升高(aHR 1.71),氯吡格雷-阿司匹林组未观察到。
核心结论
- 低LDL-C水平与接受双联抗血小板治疗的轻型缺血性卒中或高危短暂性脑缺血发作患者3个月内出血风险升高相关,尤其是使用替格瑞洛-阿司匹林者。
- 在这些患者中同时考虑LDL-C目标策略与双联抗血小板方案时,权衡风险与获益至关重要。
研究设计与样本
- 队列研究,汇总中国CHANCE试验(2009年10月至2012年7月,114个中心)与CHANCE-2试验(2019年9月至2021年3月,202个中心)两项随机双盲安慰剂对照临床试验的数据。
- 共8996例急性轻型缺血性卒中或高危短暂性脑缺血发作并接受双联抗血小板治疗的患者,排除无血清标本1066例及基线LDL-C缺失490例后,最终纳入7440例(氯吡格雷-阿司匹林组4486例,替格瑞洛-阿司匹林组2954例)。
- 中位(IQR)年龄64.32(56.56-71.30)岁,女性2479例(33.32%)。
- 两项试验患者均随访90天;数据分析时间为2022年8月至2023年5月。
主要发现
- 3个月时报告270例(3.63%)出血事件。
- LDL-C低于70 mg/dL与任何出血风险升高相关(aHR 1.48;95% CI 1.03-2.12)。
- LDL-C低于70 mg/dL与重度或中度出血风险升高相关(aHR 2.78;95% CI 1.18-6.53)。
- 替格瑞洛-阿司匹林组LDL-C水平较低时任何出血风险升高(aHR 1.71;95% CI 1.08-2.72);氯吡格雷-阿司匹林组未观察到任何出血风险升高(aHR 1.30;95% CI 0.73-2.30)。
- 在替格瑞洛-阿司匹林组或氯吡格雷-阿司匹林组中,LDL-C水平与重度或中度出血风险均无显著关联。
临床怎么用
- 原文结论指出,在这些患者中同时考虑LDL-C目标策略与双联抗血小板方案时,权衡风险与获益至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Evidence on the bleeding risk associated with low-density lipoprotein cholesterol (LDL-C) levels in patients receiving dual antiplatelet therapy (DAPT) remains sparse. OBJECTIVE: To investigate the association of LDL-C levels with bleeding risk in patients with minor ischemic stroke (MIS) or high-risk transient ischemic attack (HRTIA) receiving DAPT. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was an analysis of pooled data from 2 randomized, double-blind, placebo-controlled clinical trials in China of patients with MIS or HRTIA who were receiving DAPT: the CHANCE (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) trial enrolled patients at 114 sites from October 2009 to July 2012, and the CHANCE-2 enrolled patients at 202 centers from September 2019 to March 2021. Both sets of patients were followed up for 90 days. Data analysis was performed from August 2022 to May 2023. EXPOSURES: Baseline LDL-C levels and receipt of ticagrelor-aspirin and clopidogrel-aspirin DAPT. MAIN OUTCOMES AND MEASURES: The primary outcome was any bleeding, and the secondary outcome was severe or moderate bleeding within 3 months after randomization. The association of LDL-C levels and all outcomes was assessed by using the Cox proportional hazard model. Hazard ratios (HRs) with 95% CIs were calculated on univariable (unadjusted) Cox regression models. Adjusted HRs (aHRs) and their 95% CIs were calculated on multivariable Cox regression models. RESULTS: In total, 8996 patients with acute MIS or HRTIA who were receiving DAPT were included in the 2 trials, of whom 1066 without serum specimens and 490 patients with missing baseline LDL-C value were excluded. Finally, 7440 patients with DAPT (4486 in the clopidogrel-aspirin group and 2954 in the ticagrelor-aspirin group) were included in this study. The median (IQR) age was 64.32 (56.56-71.30) years, and 2479 patients (33.32%) were women. A total of 270 (3.63%) bleeding events were reported at 3 months, and LDL-C less than 70 mg/dL was associated with an increased risk of both any bleeding (aHR, 1.48; 95% CI, 1.03-2.12), and severe or moderate bleeding (aHR, 2.78; 95% CI, 1.18-6.53). The risk of any bleeding was increased at lower LDL-C levels in the ticagrelor-aspirin group (aHR, 1.71; 95% CI, 1.08-2.72). However, an increased risk of any bleeding was not observed in the clopidogrel-aspirin group (aHR, 1.30; 95% CI, 0.73-2.30). There was no significant association between LDL-C levels and the risk of severe or moderate bleeding in either the ticagrelor-aspirin or clopidogrel-aspirin group. CONCLUSIONS AND RELEVANCE: These findings suggest that low LDL-C levels are associated with an increased bleeding risk within 3 months among patients with MIS or HRTIA receiving DAPT, especially those taking ticagrelor-aspirin. Weighing the risks and benefits is crucial when simultaneously considering the selection of LDL-C target strategies and DAPT regimens among these patients.
引用
- Cheng A, Xue J, Wang A, et al. LDL-C Levels and Bleeding Risk in Patients Taking DAPT After Minor Ischemic Stroke or TIA. JAMA Neurol. 2024. PMID: 38436990. doi:10.1001/jamaneurol.2024.0086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。